Futura expects to dose the first patient in the late-stage study of the gel within the next few weeks as part of a trial involving 1,000 men suffering from ED, with headline data expected by the end of 2019.
Futura Medical shifts focus to MED2002 treatment as clinical trial set to begin
Quick facts: Futura Medical PLC
Price: 16.25 GBX
Market Cap: £39.91 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE